根据国家和国际指南确定原发性直肠癌术前(放)化疗的使用
该研究将15项来自不同国家和地区的指南应用于686例经MRI分期的原发性非转移性直肠癌患者,确定各指南推荐单纯手术或术前(放)化疗的患者比例。结果显示,各指南推荐术前(放)化疗的患者比例在38%至77%之间;在未开展结直肠癌筛查的一般人群中,多数指南推荐超过50%的患者接受术前/新辅助治疗。
要点
- 15项指南推荐术前(放)化疗的比例为38%至77%。
- 多数指南中,未直接手术的患者均推荐放化疗。
- 若仅推荐不可切除或切除困难者术前治疗,则9%接受放化疗后延迟手术。
核心结论
- 根据多数指南,在未开展结直肠癌筛查的一般人群中,超过50%的原发性非转移性直肠癌患者被推荐接受术前/新辅助治疗。
研究设计与样本
- 基于瑞典未选择人群的686例经MRI分期的原发性非转移性直肠癌资料,应用15项来自不同国家和地区的指南进行分析。
主要发现
- 各指南明确推荐术前(放)化疗的患者比例在38%至77%之间。
- 多数指南推荐所有未直接手术的患者接受放化疗,部分指南也推荐中危肿瘤患者接受短程放疗。
- 若仅推荐不可切除或切除困难的肿瘤接受术前治疗(如许多日本文献所述),则9%的患者接受放化疗后延迟手术。
关键数值与推荐
- 原文未报告具体推荐条款、证据等级或阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-operative radiotherapy (RT) or chemoradiotherapy (CRT) is frequently used prior to rectal cancer surgery to improve local control and survival. The treatment is administered according to guidelines, but these recommendations vary significantly between countries. Based on the stage distribution and risk factors of rectal cancers as determined by magnetic resonance imaging (MRI) in an unselected Swedish population, the use of RT/CRT according to 15 selected guidelines is described. MATERIALS AND METHODS: Selected guidelines from different countries and regions were applied to a well-characterized unselected population-based material of 686 primary non-metastatic rectal cancers staged by MRI. The fraction of patients assigned to surgery alone or surgery following pre-treatment with (C)RT was determined according to the respective guideline. RT/CRT administered to rectal cancer patients for other reasons, for example, for organ preservation or palliation, was not considered. RESULTS: The fraction of patients with a clear recommendation for pre-treatment with (C)RT varied between 38% and 77% according to the different guidelines. In most guidelines, CRT was recommended to all patients who were not operated directly, and, in others, short-course RT was also recommended to patients with intermediate risk tumours. If only non-resectable or difficult to resect tumours were recommended pre-treatment, as stated in many Japanese publications, 9% would receive CRT followed by a delay to surgery. CONCLUSIONS: According to most guidelines, well over 50% of primary non-metastatic rectal cancer patients from a general population, in which screening for colorectal cancer is not practised, are recommended treatment with pre-operative/neo-adjuvant therapy.
引用
- Hammarström K, Imam I, Korsavidou Hult N, et al. Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. Radiother Oncol. 2019. PMID: 31015111. doi:10.1016/j.radonc.2019.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。